Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura Tsujikawa, Christopher Halliday, et al.
Kidney International Reports (2017) Vol. 3, Iss. 3, pp. 711-721
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Ewelina Kulikowski, Brooke D. Rakai, Norman C.W. Wong
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 223-245
Open Access | Times Cited: 91
Bone alkaline phosphatase: An important biomarker in chronic kidney disease – mineral and bone disorder
A Nizet, Étienne Cavalier, Peter Stenvinkel, et al.
Clinica Chimica Acta (2019) Vol. 501, pp. 198-206
Closed Access | Times Cited: 90
Enhancer and super-enhancer dynamics in repair after ischemic acute kidney injury
Julia Wilflingseder, Michaela Willi, Hye‐Kyung Lee, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 85
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
José Luis Morgado‐Pascual, Sandra Rayego‐Mateos, Lucía Tejedor-Santamaria, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 83
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
Kamyar Kalantar‐Zadeh, Gregory G. Schwartz, Stephen J. Nicholls, et al.
Clinical Journal of the American Society of Nephrology (2021) Vol. 16, Iss. 5, pp. 705-716
Open Access | Times Cited: 47
Apabetalone downregulates factors and pathways associated with vascular calcification
Dean Gilham, Laura Tsujikawa, Christopher D. Sarsons, et al.
Atherosclerosis (2018) Vol. 280, pp. 75-84
Open Access | Times Cited: 58
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Kausik K. Ray, Stephen J. Nicholls, Henry Ginsberg, et al.
American Heart Journal (2019) Vol. 217, pp. 72-83
Open Access | Times Cited: 51
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
Ewelina Kulikowski, Christopher Halliday, Jan Johansson, et al.
Kidney & Blood Pressure Research (2018) Vol. 43, Iss. 2, pp. 449-457
Open Access | Times Cited: 47
Evidence of epigenetic alterations in thrombosis and coagulation: A systematic review
Markos Patsouras, P. Vlachoyiannopoulos
Journal of Autoimmunity (2019) Vol. 104, pp. 102347-102347
Closed Access | Times Cited: 40
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
Mathias Haarhaus, Kausik K. Ray, Stephen J. Nicholls, et al.
Atherosclerosis (2019) Vol. 290, pp. 59-65
Open Access | Times Cited: 36
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
Michael D. Olp, Daniel J. Sprague, Christopher G. Goetz, et al.
ACS Chemical Biology (2020) Vol. 15, Iss. 4, pp. 1036-1049
Open Access | Times Cited: 36
Histone Acetylation and Modifiers in Renal Fibrosis
Fengchen Shen, Shougang Zhuang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Vascular calcification inhibitors in chronic kidney disease
Annika Adoberg, Liisi Leis, Merike Luman, et al.
Clinica Chimica Acta (2025), pp. 120271-120271
Open Access
Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders
Hevna Dhulkifle, Mohammad Diab, Majed Ali Algonaiah, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 546-559
Open Access | Times Cited: 3
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics
Ramón Cacabelos, Juan C. Carril, Ana Sanmartín, et al.
Elsevier eBooks (2019), pp. 191-424
Closed Access | Times Cited: 28
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Niki Katsiki, Dimitri P. Mikhailidis, Maciej Banach
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 16, pp. 2007-2017
Closed Access | Times Cited: 24
Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
Mathias Haarhaus, Dean Gilham, Ewelina Kulikowski, et al.
Current Opinion in Nephrology & Hypertension (2019) Vol. 29, Iss. 1, pp. 4-15
Open Access | Times Cited: 24
ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome
Wanqi Wang, Noor A. Lokman, Tannith M. Noye, et al.
Cancer Drug Resistance (2021)
Open Access | Times Cited: 17
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia
Zachary C. Rosenthal, Daniel M. Fass, N. Connor Payne, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators
Laura Tsujikawa, Olesya A. Kharenko, Stephanie C. Stotz, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 152, pp. 113230-113230
Closed Access | Times Cited: 10
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D. Rakai, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1663-1663
Open Access | Times Cited: 6
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura Tsujikawa, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 9
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
Sylwia Wasiak, Dean Gilham, Emily Daze, et al.
Cardiovascular Therapeutics (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 13
Lipoprotein dysfunction in patients with chronic kidney disease (CKD). Pathogenesis and treatment of CKD dyslipidemia (literature review)
В. М. Ермоленко
Nephrology (Saint-Petersburg) (2024) Vol. 28, Iss. 1, pp. 13-29
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top